Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | MEN1 | O00255 | 4/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | NPC1 | O15118 | 3/20 | 0.59 |
| ▸ | RAB9A | P51151 | 3/20 | 0.59 |
| ▸ | HTT | P42858 | 3/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | FAAH | O00519 | 1/20 | 0.53 |
| ▸ | TGM2 | P21980 | 1/20 | 0.52 |
| ▸ | XBP1 | P17861 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9609808 | 0.89 | SMN1; SMN2 (0.82) | SMN1; SMN2ALDH1A1MAPTKMT2ANPC1 | |
| SCHEMBL15996876 | 0.85 | ALDH1A1 (0.55) | SMN1; SMN2ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL29191732 | 0.83 | MEN1 (0.60) | SMN1; SMN2ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL7251623 | 0.82 | SMN1; SMN2 (0.72) | SMN1; SMN2ALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL2095089 | 0.81 | ALDH1A1 (0.55) | ALDH1A1MAPTMEN1KMT2ANPC1 | |
| SCHEMBL2291115 | 0.81 | ALDH1A1 (0.61) | ALDH1A1MAPTMEN1KMT2ANPC1 | |
| SCHEMBL632848 | 0.80 | MEN1 (0.54) | SMN1; SMN2ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL17904708 | 0.80 | NPC1 (0.67) | SMN1; SMN2ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL2097995 | 0.80 | MAPT (0.70) | SMN1; SMN2ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL2097993 | 0.80 | RAB9A (0.50) | SMN1; SMN2ALDH1A1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3508473-B1 | METHOD FOR PRODUCING CARBAMIC ACID ESTER | AIST (JP) | 2021-05-26 | — | — | EP | disclosed |
| WO-2020251953-A1 | STREPTOGRAMIN COMPOSITIONS AND THE USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-12-17 | — | — | WO | disclosed |
| US-10752579-B2 | Production method of carbamic acid ester | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2020-08-25 | — | — | US | disclosed |
| US-10556889-B1 | Salvinorin derivatives | Blue Sky Pharmaceuticals, LLC (US) | 2020-02-11 | — | — | US | disclosed |
| EP-3508473-A1 | METHOD FOR PRODUCING CARBAMIC ACID ESTER | National Institute of Advanced Industrial Science and Technology (JP) | 2019-07-10 | — | — | EP | disclosed |
| US-20190185420-A1 | PRODUCTION METHOD OF CARBAMIC ACID ESTER | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2019-06-20 | — | — | US | disclosed |
| CN-109641835-A | Method for producing carbamate | 国立研究开发法人产业技术综合研究所 | 2019-04-16 | — | — | CN | disclosed |
| EP-3309148-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2018-04-18 | — | — | EP | disclosed |
| EP-2766346-B1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-03-29 | — | — | EP | disclosed |
| US-20160194274-A1 | PHENANTHRENE DERIVATIVES FOR USE AS MEDICAMENTS | VALENTIA BIOPHARMA (ES) | 2016-07-07 | — | — | US | disclosed |
| US-20090221515-A1 | MONOSACCHARIDE DERIVATIVES | RANBAXY LABORATORIES INC. (IN) | 2009-09-03 | — | — | US | disclosed |
| US-20090221515-A1 | MONOSACCHARIDE DERIVATIVES | RANBAXY LABORATORIES INC. (IN) | 2009-09-03 | — | — | US | disclosed |
| US-20090048186-A1 | Monosaccharide Derivatives as Anti-Inflammatory and/or Anti-Cancer Agents | RANBAXY LABORATORIES LIMITED (IN) | 2009-02-19 | — | — | US | disclosed |
| US-20090048186-A1 | Monosaccharide Derivatives as Anti-Inflammatory and/or Anti-Cancer Agents | RANBAXY LABORATORIES LIMITED (IN) | 2009-02-19 | — | — | US | disclosed |
| WO-2008150447-A1 | AMIDE COMPOUNDS AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2008-12-11 | — | — | WO | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
| US-4298731-A | HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1981-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048186-A1 | Monosaccharide Derivatives as Anti-Inflammatory and/or Anti-Cancer Agents | HLA-DRB1, MUC1, ASGR1 | SMN1; SMN2 4758/4885ALDH1A1 605/4885MAPT 1151/4885 |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | SMN1; SMN2 3787/4885ALDH1A1 412/4885MAPT 4299/4885 |
| US-10556889-B1 | Salvinorin derivatives | OPRD1, OPRK1, OPRL1 | SMN1; SMN2 1186/4885ALDH1A1 866/4885MAPT 4659/4885 |
| US-20190185420-A1 | PRODUCTION METHOD OF CARBAMIC ACID ESTER | CA2, CA7, CA4 | SMN1; SMN2 3068/4885ALDH1A1 3215/4885MAPT 2148/4885 |
| US-20090221515-A1 | MONOSACCHARIDE DERIVATIVES | HLA-DRB1, MUC1, FUT5 | SMN1; SMN2 4797/4885ALDH1A1 402/4885MAPT 1370/4885 |
| US-10752579-B2 | Production method of carbamic acid ester | CA2, CA7, CA4 | SMN1; SMN2 3068/4885ALDH1A1 3215/4885MAPT 2148/4885 |
| US-20160194274-A1 | PHENANTHRENE DERIVATIVES FOR USE AS MEDICAMENTS | HTT, TARDBP, ATXN2 | SMN1; SMN2 12/4885ALDH1A1 2216/4885MAPT 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.